APA

De Keyser E., Busard C. I., Lanssens S., Meuleman L., Hutten B. A., Costanzo A., van den Reek J. M., Zweegers J., Lambert J. & Spuls P. I. (20200323). Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab. : Therapeutic drug monitoring.

Chicago

De Keyser Eline, Busard Celine I, Lanssens Sven, Meuleman Lieve, Hutten Barbara A, Costanzo Antonio, van den Reek Juul M, Zweegers Jeffrey, Lambert Jo and Spuls Phyllis I. 20200323. Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab. : Therapeutic drug monitoring.

Harvard

De Keyser E., Busard C. I., Lanssens S., Meuleman L., Hutten B. A., Costanzo A., van den Reek J. M., Zweegers J., Lambert J. and Spuls P. I. (20200323). Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab. : Therapeutic drug monitoring.

MLA

De Keyser Eline, Busard Celine I, Lanssens Sven, Meuleman Lieve, Hutten Barbara A, Costanzo Antonio, van den Reek Juul M, Zweegers Jeffrey, Lambert Jo and Spuls Phyllis I. Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab. : Therapeutic drug monitoring. 20200323.